Roorkee, nestled in the Haridwar district of Uttarakhand, has quietly grown into a bustling pharmaceutical manufacturing hub. The city’s strategic location, skilled workforce, and strong infrastructure have attracted numerous drug producers, laboratories, and third‑party manufacturing firms. This thriving ecosystem plays a pivotal role in enhancing medicine availability and driving affordability across North India and beyond.
Among the standout players is Supermax Laboratories, a trusted name in the region’s medicine landscape. Coupled with other reputable firms, they collectively shape the future of healthcare delivery in the region and beyond.
Why Roorkee? A Pharma Powerhouse
- Strategic Logistics and Infrastructure
Roorkee features robust road and rail connectivity, bolstered by proximity to major markets like Delhi and Lucknow. Government initiatives such as the PLI scheme and SIIDCUL’s industrial estates have further elevated the city’s manufacturing appeal. - Skilled Talent Pool
With Roorkee’s academic institutions producing talented technicians and engineers, the city sustains high manufacturing standards and operational excellence. - Global Quality Compliance
Companies in Roorkee frequently uphold WHO‑GMP and ISO certifications, enabling them to serve both domestic and international markets while maintaining top-tier quality.
Industry Highlights: Leading Pharma Players in Roorkee
Supermax Laboratories (Featured Highlight)
[Here, you’d insert a brief profile of Supermax — mention founding year, core strengths, any notable product lines or certifications. If you provide details, I can help integrate them here.]
Aglowmed Ltd.
An established Roorkee‑based enterprise, Aglowmed boasts WHO‑GMP certification and specializes in diverse therapeutic categories including anti‑infectives, pediatric drugs, respiratory, and gynecology products.
Axa Parenterals Ltd.
Axa delivers a broad portfolio of parenteral formulations—from injectables to eye, ear, and nasal drops. Their ultramodern plant adheres to US FDA and EU GMP standards, capable of producing substantial volumes annually.
Pulse Pharmaceuticals Pvt. Ltd.
Since its inception in 1997, Pulse has expanded rapidly and exports to Southeast Asia, Russia, CIS, and Africa. Their expansive product line includes treatments like Doloneuron NT, Meconeuron Inj., and more.
Esteem Pharmaceuticals India Pvt. Ltd.
Established in 2000, Esteem offers a broad spectrum—from antibiotics to gynecology and anti‑fungals—while prioritizing inclusive distribution networks throughout Uttarakhand.
Addapt Lifecare Pharmaceuticals
Founded in 2006, this company emphasizes hormone drugs and medications, offering extensive marketing reach, modern warehousing, and a wide product portfolio of around 500 SKUs.
Hiral Labs Ltd., Biocenna Healthcare, Leroi Pharma, Lucent Biotech, Spectrum Formulation, Raczom Pharma, and more
Roorkee’s roster includes a rich variety of specialty and contract manufacturers—ranging from formulations to biotechnologies—offering diverse pharmaceutical services.
Ensuring Quality: Rules & Challenges
In June 2025, the CDSCO flagged 15 medications manufactured in Haridwar and Roorkee as “Not of Standard Quality” (NSQ), including drugs like Albendazole, Amoxycillin, Paracetamol, and Dapagliflozin. Investigations revealed that some firms registered locations without actual manufacturing facilities, prompting regulatory action.
This incident underscores the critical need for stringent quality control and transparency—a reminder for stakeholders regarding certification, inspections, and accountability.
Conclusion: Driving Affordable Healthcare Forward
Roorkee’s pharmaceutical ecosystem—powered by firms like Aglowmed, Axa Parenterals, Pulse, Esteem, Addapt, and potentially Supermax Laboratories—reflects the region’s resilience, diversity, and dedication to healthcare impact.
Their adherence to global standards, commitment to affordability, and expanding export footprint underscore Roorkee’s evolving role as a vital medicine hub. As the industry moves forward, upholding quality and regulatory compliance remains essential—ensuring patients across India and worldwide receive the safe, affordable medications they rely on.
